


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listings of Claims

1. – 40. (Cancelled)

41. (New) A compound of the formula:



wherein R represents C₂-C₁₀ alkyl, or a pharmaceutically acceptable salt thereof.

42. (New) The compound or salt according to claim 41 wherein R represents 2-ethyl-butyl, isobutyl, 3-methyl-butyl, decyl, or ethyl.

43. (New) The compound or salt according to claim 42 wherein R represents 2-ethyl-butyl.

44. (New) The compound or salt according to claim 42 wherein R represents isobutyl.

45. (New) The compound or salt according to claim 42 wherein R represents 3-methyl-butyl.

46. (New) The compound or salt according to claim 42 wherein R represents decyl.

47. (New) The compound or salt according to claim 42 wherein R represents ethyl.

48. (New) A salt selected from the group consisting of $(3S,4aR,6R,8aR)$ -6-[2-(1H-Tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester trifluoroacetate salt; $(3S,4aR,6R,8aR)$ -6-[2-(1H-Tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid isobutyl ester trifluoroacetate salt; $(3S,4aR,6R,8aR)$ -6-[2-(1H-Tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid 3-methyl butyl ester trifluoroacetate salt; $(3S,4aR,6R,8aR)$ -6-[2-(1H-Tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid decyl ester trifluoroacetate salt; and $(3S,4aR,6R,8aR)$ -6-[2-(1H-Tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid ethyl ester hydrochloride salt.

49. (New) A compound which is $(3S,4aR,6R,8aR)$ -6-[2-(1H-Tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester.

50. (New) A compound which is $(3S,4aR,6R,8aR)$ -6-[2-(1H-Tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid isobutyl ester.


51. (New) A compound which is $(3S,4aR,6R,8aR)$ -6-[2-(1H-Tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid 3-methyl butyl ester.

52. (New) A compound which is $(3S,4aR,6R,8aR)$ -6-[2-(1H-Tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid decyl ester.

53. (New) A compound which is $(3S,4aR,6R,8aR)$ -6-[2-(1H-Tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid ethyl ester.

54. (New) $(3S,4aR,6R,8aR)$ -6-[2-(1H-Tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid methyl ester, or a pharmaceutically acceptable salt thereof, in isolated form.


55. (New) A pharmaceutical composition which comprises a compound of the formula:



wherein R represents C₁-C₁₀ alkyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

56. (New) The pharmaceutical composition according to claim 55 which comprises (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester, or pharmaceutically acceptable salt thereof; (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid isobutyl ester, or pharmaceutically acceptable salt thereof; (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid 3-methyl-butyl ester, or a pharmaceutically acceptable salt thereof; (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid decyl ester, or a pharmaceutically acceptable salt thereof; or (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid ethyl ester, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier.

57. (New) A method of treating pain, which comprises administering to a patient an effective amount of a compound of the formula:




wherein R represents C₁-C₁₀ alkyl, or a pharmaceutically acceptable salt thereof.

58. (New) The method according to claim 57, which comprises administering to a patient an effective amount of (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester, or pharmaceutically acceptable salt thereof; (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid isobutyl ester, or

pharmaceutically acceptable salt thereof; (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid 3-methyl-butyl ester, or a pharmaceutically acceptable salt thereof; (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid decyl ester, or a pharmaceutically acceptable salt thereof; or (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid ethyl ester, or a pharmaceutically acceptable salt thereof.

59. (New) A method of treating migraine, which comprises administering to a patient an effective amount of a compound of the formula:



wherein R represents C₁-C₁₀ alkyl, or a pharmaceutically acceptable salt thereof.

60. (New) The method according to claim 59, which comprises administering to a patient an effective amount of (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester, or pharmaceutically acceptable salt thereof; (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid isobutyl ester, or pharmaceutically acceptable salt thereof; (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid 3-methyl-butyl ester, or a pharmaceutically acceptable salt thereof; (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid decyl ester, or a pharmaceutically acceptable salt thereof; or (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl]-1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid ethyl ester, or a pharmaceutically acceptable salt thereof.